SUMMARY Ultrasound assessment of ovarian volume, follicular size, and uterine growth was undertaken in 40 normal premenarcheal girls aged 6 months to 14 years. Ovarian follicles were detected from 6 months of age and increased in size and number, so that after the age of 8-5 years there was a progressive increase in the incidence of 'megalocystic' appearance. Eight girls with idiopathic precocious puberty had large megalocystic ovaries which regressed on treatment with gonadotrophin releasing hormone analogue. These findings contrasted with those seen in two prepubertal patients with hypogonadotrophic hypogonadism in whom the natural sequence of ovarian development was greatly accelerated by pulsatile administration of native gonadotrophin releasing hormone. We have used ultrasound as a non-invasive method of assessing ovarian size and structure as well as uterine changes in normal children. We have compared the ovarian morphological changes of normal childhood with those seen during the suppression of idiopathic precocious puberty and during induction of puberty in patients with hypogonadotrophic hypogonadism.
The initiation and maintenance of human sexual development requires the pulsatile release of gonadotrophins from the pituitary in response to pulsatile gonadotrophin releasing hormone.' Treatment of hypogonadotrophic hypogonadism with pulsatile gonadotrophin releasing hormone can restore reproductive function in both males2 and females.3 The use of analogues that desensitise the pituitary response to endogenous gonadotrophin releasing hormone has been established as an effective treatment of idiopathic precocious puberty.4 Buserelin (6-D-Ser-(TBu)-GnRH-(1- 9) We have used ultrasound as a non-invasive method of assessing ovarian size and structure as well as uterine changes in normal children. We have compared the ovarian morphological changes of normal childhood with those seen during the suppression of idiopathic precocious puberty and during induction of puberty in patients with hypogonadotrophic hypogonadism.
Patients and methods
We studied 40 normal premenarcheal girls, eight with idiopathic precocious puberty, four of whom were treated with analogue, and two with delayed puberty treated by pulsatile administration of native gonadotrophin releasing hormone. All ultrasound scans were performed by JA using an Emisonic 4201 static scanner with a long focussed 3 5 mHz transducer and more recently an Aloka sector scanner with 3-5 mHz long focussed and 5-0 mHz transducers. Ovarian volume was calculated by measuring length, width, and depth and by assuming the shape to be ellipsoid.12 Uterine size was estimated from measurements of maximum length and depth in sagittal section and expressed as cross sectional area.
Four of the patients with precocious puberty were treated with Buserelin (gonadotrophin releasing hormone analogue), given intranasally between 400 and 800 ,ug daily in divided doses. Native gonado-116 trophin releasing hormone was administered subcutaneously in pulses using a miniature infusion pump:'3 a dose of 15 ,ug was administered at 90 minute intervals throughout 24 hours.
Informed parental consent was given for normal control patients.
Results
Ovarian volume gradually increased during childhood from a mean of 1 cm3 at 2 years of age to a mean of 2 cm3 at 12 years (Fig. 1) . A maximum follicular diameter of 7 mm was normal in early childhood (Fig. 2) . We define a 'megalocystic' ovary as one containing more than six follicles greater than 4 mm in diameter present in each ovary (Fig. 3 ). There was a progressive increase in the proportion of normal girls with megalocystic ovaries over the age of 8*5 years ( Fig. 1 ). Uterine size was unchanged from 6 months to 10 years, mean cross sectional area was 2 cm2 (Fig. 4 ) and there was a rapid increase in uterine size after the age of 10 years associated with the onset of puberty. At presentation, all eight girls with idiopathic precocious puberty had large megalocystic ovaries, greater than 3 cm3 in volume (Fig. 1) , which approached or fell within the normal adult range. Maximum follicular diameter was within the normal 0 0000 range for age (Fig. 2) . All eight had uterine cross sectional areas greater than 4 cm2 (Fig. 4) (Fig. 6 ). The pattern of growth of the ovary and uterus in response to treatment is shown in Fig. 7 . After 8 weeks of treatment the ovaries became megalocystic. During a 10 day period of mechanical pump failure both ovaries and uterine size decreased, We have found that pelvic ultrasound assessment is helpful in the diagnosis and classification of precocious puberty. The presence of a large uterus with a cross sectional area greater than 4 cm2 confirms this diagnosis. In addition to the uterine changes, the ovaries in idiopathic precocious puberty are large, approach adult size, and are always megalocystic. An ovarian volume of greater than 3 cm3 is outside the normal range and confirms a diagnosis of idiopathic precocious puberty. Treatment with gonadotrophin releasing hormone analogue is associated with regression of the megalocystic ovarian appearance.
In our experience of inducing puberty in patients with hypogonadotrophic hypogonadism, changes occur in ovarian morphology and uterine size which closely resemble those seen in normal puberty. The megalocystic appearance is an ovarian response to pulsatile gonadotrophin secretion. We hypothesise that pulsatile secretion of gonadotrophin releasing hormone in low amplitude and long periodicity leads to the beginning of ovarian maturation early in childhood, before there are any clinical signs of puberty. A phase of megalocystic ovarian appearance occurs before the development of a dominant follicle. These changes can be reproduced in patients with hypogonadotrophic hypogonadism treated with pulsatile gonadotrophin releasing hormone by varying pulse frequency and amplitude. The megalocystic ovarian appearance is dependent on pulsatile gonadotrophin releasing hormone secretion and can be suppressed with analogue.
Ultrasound imaging has a key role in the diagnosis and management of disorders of sexual maturation, reducing the requirement for more complex biochemical measurements 
